Evidence map›Paper›PMID 34620931›Full record

ArticleScientific reports2021

A multicenter case-control study of the effect of e-nos VNTR polymorphism on upper gastrointestinal hemorrhage in NSAID users.

Narmeen Mallah, Maruxa Zapata-Cachafeiro, Carmelo Aguirre, Eguzkiñe Ibarra-García, Itziar Palacios-Zabalza, Fernando Macías García, Julio Iglesias García, María Piñeiro-Lamas, Luisa Ibáñez, Xavier Vidal and 6 more

Open access · goldAbstract readMulticenter Study
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Pharmacogenetics of Antiplatelet Therapy.Annual review of pharmacology and toxicology · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 7 institutions in 1 country.

Narmeen MallahDepartment of Preventive Medicine, University of Santiago de Compostela, Santiago de Compostela, Spain.
Maruxa Zapata-CachafeiroDepartment of Preventive Medicine, University of Santiago de Compostela, Santiago de Compostela, Spain. maruxa.zapata@usc.es.
Carmelo AguirreBiocruces Bizkaia Health Research Institute, Pharmacotherapy Group, Bizkaia, Spain.
Eguzkiñe Ibarra-GarcíaBiocruces Bizkaia Health Research Institute, Pharmacotherapy Group, Bizkaia, Spain.
Itziar Palacios-ZabalzaBiocruces Bizkaia Health Research Institute, Pharmacotherapy Group, Bizkaia, Spain.
Fernando Macías GarcíaDepartment of Gastroenterology and Hepatology, University Hospital of Santiago de Compostela, Santiago de Compostela, Spain.
Julio Iglesias GarcíaDepartment of Gastroenterology and Hepatology, University Hospital of Santiago de Compostela, Santiago de Compostela, Spain.
María Piñeiro-LamasConsortium for Biomedical Research in Epidemiology and Public Health (CIBER en Epidemiología Y Salud Pública- CIBERESP), Carlos III Health Institute, Madrid, Spain.
Luisa IbáñezDepartment of Pharmacology, Therapeutics and Toxicology, Clinical Pharmacology Service, Catalonian Institute of Pharmacology, Vall d'Hebron University Teaching Hospital, Autonomous University, Barcelona, Spain.
Xavier VidalDepartment of Pharmacology, Therapeutics and Toxicology, Clinical Pharmacology Service, Catalonian Institute of Pharmacology, Vall d'Hebron University Teaching Hospital, Autonomous University, Barcelona, Spain.
Lourdes VendrellDepartment of Pharmacology, Therapeutics and Toxicology, Clinical Pharmacology Service, Catalonian Institute of Pharmacology, Vall d'Hebron University Teaching Hospital, Autonomous University, Barcelona, Spain.
Luis Martin-AriasCentre for Research On Drug Safety (CESME), Valladolid University, Valladolid, Spain.
María Sáinz GilCentre for Research On Drug Safety (CESME), Valladolid University, Valladolid, Spain.
Verónica Velasco-GonzálezCentre for Research On Drug Safety (CESME), Valladolid University, Valladolid, Spain.
Ángel Salgado-BarreiraDepartment of Preventive Medicine, University of Santiago de Compostela, Santiago de Compostela, Spain.
Adolfo FigueirasDepartment of Preventive Medicine, University of Santiago de Compostela, Santiago de Compostela, Spain.
Universidad de Valladolid · ESUniversidade de Santiago de Compostela · ESInstituto de Salud Carlos III · ESOsakidetza · ESBioCruces Health research Institute · ESCentro de Investigación Biomédica en Red de Epidemiología y Salud Pública · ESInstituto de Investigación Sanitaria de Santiago · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bleeding in non-steroidal anti-inflammatory drug (NSAID) users limited their prescription. This first multicenter full case-control study (325 cases and 744 controls), explored the association of e-NOS intron 4 variable number tandem repeat (VNTR) polymorphism with upper gastrointestinal hemorrhage (UGIH) in NSAID exposed and unexposed populations and assessed any interaction between this polymorphism and NSAIDs. NSAID users carrying e-NOS intron 4 wild type genotype or VNTR polymorphism have higher odds of UGIH than those unexposed to NSAIDs [Odds Ratio (OR): 6.62 (95% Confidence Interval (CI): 4.24, 10.36) and OR: 5.41 (95% CI 2.62, 11.51), respectively], with no effect modification from VNTR polymorphism-NSAIDs interaction [Relative Excess Risk due to Interaction (RERI): -1.35 (95% CI -5.73, 3.03); Synergism Index (S): 0.77 (95% CI 0.31, 1.94)]. Similar findings were obtained for aspirin exposure. Non-aspirin NSAID users who carry e-NOS intron 4 VNTR polymorphism have lower odds of UGIH [OR: 4.02 (95% CI 1.85, 8.75) than those users with wild type genotype [OR: 6.52 (95% CI 4.09, 10.38)]; though the interaction estimates are not statistically significant [RERI: -2.68 (95% CI -6.67, 1.31); S: 0.53 (95% CI 0.18, 1.55)]. This exploratory study suggests that the odds of UGIH in NSAID or aspirin users does not modify according to patient´s e-NOS intron 4 genotype.

Indexed as

Disease SusceptibilityMinisatellite RepeatsPolymorphism, GeneticAdultAgedAllelesAnti-Inflammatory Agents, Non-SteroidalCase-Control StudiesFemaleGastrointestinal HemorrhageGenetic Predisposition to DiseaseGenotypeHumansIntronsMaleMiddle AgedAnti-Inflammatory Agents, Non-SteroidalNitric Oxide Synthase Type IIINOS3 protein, human

Identifiers

PMID34620931
PMCPMC8497469
OpenAlexW3204760089

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.